Glioblastoma Multiforme, Diagnosis and Treatment; Recent Literature Review

Current Medicinal Chemistry
Ron BatashMoshe Schaffer

Abstract

Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor, with an incidence of 3.19 cases per 100,000 person years and remarkably poor prognosis showing a 5-year survival rate of 4-5%, and only a 26-33% survival rate at 2 years in clinical trials. In this paper, we review the different types of treatment modalities based on the relevant databases. Methods of diagnosis will be described briefly. Systemic compilation of the relevant literature. Today's treatments cannot cure GBM patients but only extend their overall survival. The use of chemoradiation, immunotherapy, and radio sensitizers as an adjuvant therapy cannot reduce the high rates of recurrence within a few months after treatment. Radiotherapy will remain the backbone of the treatment but new treatment modalities must be developed.

Citations

Nov 27, 2018·Carcinogenesis·Raghupathy VengojiMuzafar A Macha
Dec 2, 2018·The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutica·Guillaume PeyragaAnne Laprie
Aug 21, 2019·In Vitro Cellular & Developmental Biology. Animal·Xuefeng TanHaoming Li
Oct 30, 2019·Biomolecules·Hee Yeon KimHyonchol Jang
Sep 23, 2020·The Journal of International Medical Research·Xu GuoHongyu Zhao
Jun 30, 2019·Life Science Alliance·Vidhya M RaviDieter Henrik Heiland
Aug 31, 2019·Phytotherapy Research : PTR·Paulo L C CoelhoSilvia L Costa
Jul 16, 2020·Bioscience Reports·Yu ZhangHu-Bin Duan
Jun 19, 2020·International Journal of Molecular Sciences·Tuyen T Dang, Julio C Morales
Oct 6, 2020·BioMed Research International·Yong'an JiangRu'en Liu
Jul 2, 2019·Experimental and Therapeutic Medicine·Ye ZhangHaozhe Piao
Sep 7, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Sonja DragojevicDrazen Raucher
Sep 19, 2020·PloS One·Lavinia-Lorena PruteanuDavid Stanley Bailey
Sep 15, 2020·JCO Precision Oncology·Musa AlharbiMalak Abedalthagafi
Jun 20, 2020·The Journal of International Medical Research·Jing LiuQin Zhou
Oct 20, 2018·Experimental & Molecular Medicine·Hee Yeon KimHyonchol Jang
Sep 26, 2019·Frontiers in Oncology·Zerong TianJianguo Xu
Feb 13, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Sahar SafaeeBehzad Baradaran
Dec 15, 2020·Frontiers in Oncology·Bárbara Paranhos CoelhoMarilene Hohmuth Lopes
Jan 7, 2021·Cancer Gene Therapy·M MurdoccaF Sangiuolo
Oct 17, 2020·International Journal of Nanomedicine·Pawel MisiakAgnieszka Z Wilczewska

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Cancer Stem Cells in Glioblastoma

Glioblastoma is the most common and aggressive type of brain tumor. It contains a population of tumor initiating stem cell-like cells known as cancer stem cells. Investigations are ongoing into these cancer stem cells found in these solid tumors which are highly resistance to treatment. Here is the latest research on cancer stem cells in glioblastoma.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.